119 reports of this reaction
1.7% of all ATAZANAVIR SULFATE reports
#10 most reported adverse reaction
SUICIDAL IDEATION is the #10 most commonly reported adverse reaction for ATAZANAVIR SULFATE, manufactured by Aurobindo Pharma Limited. There are 119 FDA adverse event reports linking ATAZANAVIR SULFATE to SUICIDAL IDEATION. This represents approximately 1.7% of all 6,992 adverse event reports for this drug.
Patients taking ATAZANAVIR SULFATE who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is a less commonly reported adverse event for ATAZANAVIR SULFATE, but still significant enough to appear in the safety profile.
In addition to suicidal ideation, the following adverse reactions have been reported for ATAZANAVIR SULFATE:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 119 FDA reports for ATAZANAVIR SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 1.7% of all adverse event reports for ATAZANAVIR SULFATE, making it a notable side effect.
If you experience suicidal ideation while taking ATAZANAVIR SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.